Thank you again for the LiveDrop demo last week. We greatly appreciated the overall experience! Fast priming protocol and robustness of the priming method - Easy recovery of the generated emulsion - Low dead volume - Real-time visual monitoring of the droplet generation process I greatly appreciated the expertise of both colleagues, as well as their dedication to adapt to our needs and planned experiments. Explanations were always clear and detailed.

Hit discovery for antibodies was mainly achieved by hybridoma technology and from libraries displayed by phage, yeast, or mammalian cells. Despite these methods being streamlined and successful, drawbacks and lack of delivery of hits is common for membrane proteins. The development of microfluidic technologies such as ModaFlow™ with the ability to compartmentalise cells within picoliter droplets will revolutionise the screening and the discovery of binders through the pre-screening of IgG secreting B cells followed by the co-incubation of B cells with cells expressing the target of interest.

"Droplet microfluidics integrated with LiveDrop’s advanced bioassays is revolutionizing immunology research. These tools enable high-throughput B-cell screening (sequencing?), monoclonal antibody discovery, and single-cell antibody response studies with unmatched precision. A game-changer technology to support innovation in Life Sciences. By rapidly screening plasma cells and Fc receptor interactions, LiveDrop drive breakthroughs in autoimmune and allergy therapies, transforming our understanding of human immunity." — Dr. Adrien Boes, CER Groupe, Belgium